Henlius Doses First Patient In China For Ophthalmic Bevacizumab
Follows US FDA Approving Henlius’ Investigational New Drug Application
Chinese firms Shanghai Henlius Biotech and Essex Bio-Technology have announced a key milestone in their Chinese Phase I clinical study for the HLX04-O biosimilar bevacizumab candidate to treat wet age-related macular degeneration.
You may also be interested in...
China’s Henlius has received international recognition of Phase I and III clinical trial results for its bevacizumab biosimilar, HLX04, providing “strong evidence for the efficacy and safety similarity between HLX04 and the reference bevacizumab.” The company has submitted its NDA for the product to the NMPA for various indications.
The sponsor of what could become the EU’s first approved ophthalmic formulation of bevacizumab needs to address outstanding issues raised by the European Medicines Agency about its filing.
Shanghai Henlius Biotech has struck a co-development and licensing deal with fellow Chinese firm Essexor biosimilar bevacizumab to treat ophthalmic diseases.